{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:08:07Z","timestamp":1789384087014,"version":"build-2803163510"},"reference-count":137,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Sci.","Medical Sciences"],"abstract":"<jats:p>Asthma and sinonasal diseases, particularly chronic rhinosinusitis with nasal polyps (CRSwNP), frequently coexist as part of the United Airway Disease (UAD), reflecting shared inflammatory pathways and physiopathologic mechanisms. They both significantly contribute as additional comorbidities to patient burden of symptoms and disease severity, and may guide the treatment approach, particularly when presenting together. The aim of this review was to explore the clinical interplay between asthma and sinonasal diseases, emphasizing epidemiologic links, shared immunologic pathways, and emerging management strategies, namely biologic therapies targeting type 2 (T2) inflammation. This approach enables integrated diagnostic and therapeutic approaches by targeting specific inflammatory mediators in a precision-medicine perspective. This may lead to a higher chance of achieving better outcomes in both upper and lower airways. Future studies should refine the treatment selection and evaluate long-term effects of biologic therapy across the upper and lower airways.<\/jats:p>","DOI":"10.3390\/medsci14050568","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:19:41Z","timestamp":1789381181000},"page":"568","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Asthma and Sinonasal Diseases: Shared Clinical Comorbidities, Inflammatory Pathways and Management Strategies"],"prefix":"10.3390","volume":"14","author":[{"given":"Francesca","family":"Cefaloni","sequence":"first","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3954-8620","authenticated-orcid":false,"given":"Enrico","family":"Schiavi","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, AOU Policlinico Umberto I, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3719-8913","authenticated-orcid":false,"given":"Matteo","family":"Morviducci","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5761-7018","authenticated-orcid":false,"given":"Eugenio","family":"De Corso","sequence":"additional","affiliation":[{"name":"Department of Medicine & Surgery, Section of Otorhinolaryngology, Santa Maria Della Misericordia\u2019s Hospital, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Brunori","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillo Facial Sciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Masieri","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillo Facial Sciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3042-0765","authenticated-orcid":false,"given":"Matteo","family":"Bonini","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, AOU Policlinico Umberto I, 00185 Rome, Italy"},{"name":"National Heart and Lung Institute (NHLI), Imperial College London, London SW7 2AZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/02770903.2021.1879130","article-title":"Manifesto on united airways diseases (UAD): An Interasma (global asthma association\u2014GAA) document","volume":"59","author":"Tiotiu","year":"2022","journal-title":"J. Asthma"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jaci.2024.10.007","article-title":"Upper airway comorbidities of asthma","volume":"154","author":"Jung","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/alr.23090","article-title":"International consensus statement on allergy and rhinology: Allergic rhinitis\u20142023","volume":"13","author":"Wise","year":"2023","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Licari, A., Castagnoli, R., Denicol\u00f2, C.F., Rossini, L., Marseglia, A., and Marseglia, G.L. (2017). The Nose and the Lung: United Airway Disease?. Front. Pediatr., 5.","DOI":"10.3389\/fped.2017.00044"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00408-009-9179-x","article-title":"Time Interval and the Factors Associated with the Development of Asthma in Patients with Allergic Rhinitis","volume":"187","author":"Mahesh","year":"2009","journal-title":"Lung"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Savour\u00e9, M., Bousquet, J., Leynaert, B., Ribet, C., Goldberg, M., Zins, M., Jacquemin, B., and Nadif, R. (2023). Asthma is associated with increased severity and duration of rhinitis: A study with the Allergic Rhinitis and its Impact on Asthma classes in the Constances cohort. Clin. Transl. Allergy, 13.","DOI":"10.1002\/clt2.12316"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/cea.13276","article-title":"Non-atopic rhinitis at age 6 is associated with subsequent development of asthma","volume":"49","author":"Carr","year":"2019","journal-title":"Clin. Exp. Allergy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11882-022-01027-0","article-title":"Clinical Evidence of Type 2 Inflammation in Non-allergic Rhinitis with Eosinophilia Syndrome: A Systematic Review","volume":"22","author":"Seccia","year":"2022","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4193\/Rhin17.255","article-title":"The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: A large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinol. J."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Toppila-Salmi, S., H\u00e4llfors, J., Aakko, J., Mannerstr\u00f6m, B., Nieminen, K., Telg, G., and Lehtim\u00e4ki, L. (2022). The burden of chronic rhinosinusitis with nasal polyps and its relation to asthma in Finland. Clin. Transl. Allergy, 12.","DOI":"10.1002\/clt2.12200"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Philpott, C.M., Erskine, S., Hopkins, C., Kumar, N., Anari, S., Kara, N., Sunkaraneni, S., Ray, J., Clark, A., and Wilson, A. (2018). Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: Data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respir. Res., 19.","DOI":"10.1186\/s12931-018-0823-y"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/alr.21674","article-title":"Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes","volume":"6","author":"Promsopa","year":"2016","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"105947","DOI":"10.1016\/j.rmed.2020.105947","article-title":"Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry","volume":"166","author":"Canonica","year":"2020","journal-title":"Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9589","DOI":"10.1038\/s41598-020-66479-8","article-title":"Bidirectional association between asthma and chronic rhinosinusitis: Two longitudinal follow-up studies using a national sample cohort","volume":"10","author":"Ryu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.anai.2018.02.005","article-title":"Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with asthma onset","volume":"120","author":"Won","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/JAA.S517258","article-title":"Impact of Comorbid Asthma on Life Quality of Patients with Chronic Rhinosinusitis and Nasal Polyps","volume":"18","author":"Wu","year":"2025","journal-title":"J. Asthma Allergy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1183\/09031936.00121308","article-title":"Influence of comorbid conditions on asthma","volume":"33","author":"Boulet","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1016\/j.jaip.2021.09.003","article-title":"Asthma and Three Colinear Comorbidities: Obesity, OSA, and GERD","volume":"9","author":"Althoff","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lemmetyinen, R.E., Toppila-Salmi, S.K., But, A., Renkonen, R., Pekkanen, J., Haukka, J., and Karjalainen, J. (2024). Comorbidities associated with adult asthma: A population-based matched cohort study in Finland. BMJ Open Respir. Res., 11.","DOI":"10.1136\/bmjresp-2023-001959"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11882-024-01184-4","article-title":"Current Review of Comorbidities in Chronic Rhinosinusitis","volume":"25","author":"Choi","year":"2025","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"108344","DOI":"10.1016\/j.rmed.2025.108344","article-title":"Asthma-OSA overlap syndrome: A distinct endophenotype?","volume":"248","author":"Fabozzi","year":"2025","journal-title":"Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41533-020-00194-9","article-title":"Impact of comorbid conditions on asthmatic adults and children","volume":"30","author":"Kaplan","year":"2020","journal-title":"npj Prim. Care Respir. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/all.13370","article-title":"Comorbid \u201ctreatable traits\u201d in difficult asthma: Current evidence and clinical evaluation","volume":"73","author":"Tay","year":"2018","journal-title":"Allergy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1081-1206(10)60309-2","article-title":"Obstructive sleep apnea syndrome and asthma: The role of continuous positive airway pressure treatment","volume":"101","author":"Alkhalil","year":"2008","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/resp.14518","article-title":"Vocal cord dysfunction\/inducible laryngeal obstruction\u20142022 Melbourne Roundtable Report","volume":"28","author":"Leong","year":"2023","journal-title":"Respirology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"16250","DOI":"10.20452\/pamw.16250","article-title":"Asthma and comorbidities: Recent advances","volume":"132","author":"Cazzola","year":"2022","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Simmalee, K., Kawamatawong, T., Vitte, J., Demoly, P., and Lumjiaktase, P. (2025). Exploring the pathogenesis and clinical implications of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO): A narrative review. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1514846"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/cea.12907","article-title":"Cigarette smoking increases bronchial mucosal IL-17A expression in asthmatics, which acts in concert with environmental aeroallergens to engender neutrophilic inflammation","volume":"47","author":"Siew","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"ref_30","first-page":"384","article-title":"Allergic Sensitization in Elderly Patients with Chronic Obstructive Pulmonary Disease","volume":"57","author":"Itabashi","year":"1990","journal-title":"Respiration"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.resinv.2021.11.004","article-title":"Bronchiectasis in severe asthma and asthmatic components in bronchiectasis","volume":"60","author":"Matsumoto","year":"2022","journal-title":"Respir. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"01087","DOI":"10.1183\/23120541.01087-2024","article-title":"Bronchiectasis and sinonasal diseases: A narrative review","volume":"11","author":"Simonetta","year":"2025","journal-title":"ERJ Open Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"220202","DOI":"10.1183\/16000617.0202-2022","article-title":"Strength of association between comorbidities and asthma: A meta-analysis","volume":"32","author":"Rogliani","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1378\/chest.109.2.316","article-title":"Prevalence of Gastroesophageal Reflux Symptoms in Asthma","volume":"109","author":"Field","year":"1996","journal-title":"Chest"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4193\/Rhin16.177","article-title":"Association of gastro-oesophageal reflux and chronic rhinosinusitis: Systematic review and meta-analysis","volume":"55","author":"Leason","year":"2017","journal-title":"Rhinology"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"The American Lung Association Asthma Clinical Research Centers (2009). Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma. N. Engl. J. Med., 360, 1487\u20131499.","DOI":"10.1056\/NEJMoa0806290"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1164\/rccm.200507-1167OC","article-title":"Effects of Esomeprazole 40 mg Twice Daily on Asthma","volume":"173","author":"Kiljander","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_38","first-page":"987","article-title":"Asthmatics with Gastroesophageal Reflux: Long Term Results of A Randomized Trial of Medical and Surgical Antireflux Therapies","volume":"98","author":"Sontag","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ohn.612","article-title":"Evaluating the Association of Obesity and Chronic Rhinosinusitis: A Systematic Review and Meta-analysis","volume":"170","author":"Hoying","year":"2024","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoto.2024.2705","article-title":"Chronic Rhinosinusitis and Mental Health","volume":"150","author":"Khan","year":"2024","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.2147\/JIR.S311640","article-title":"Insights into the Implications of Coexisting Type 2 Inflammatory Diseases","volume":"14","author":"McCormick","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S2213-2600(25)00135-3","article-title":"Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): A multinational study of asthma cohorts","volume":"13","author":"Kurukulaaratchy","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.jaip.2023.05.011","article-title":"The Unified Airway Hypothesis: Evidence From Specific Intervention with Anti\u2013IL-5 Biologic Therapy","volume":"11","author":"Bachert","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0091-6749(99)70320-9","article-title":"Allergic rhinobronchitis:The asthma-allergic rhinitis link","volume":"104","author":"Simons","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1164\/ajrccm.159.2.9801022","article-title":"Comparison between nasal and bronchial inflammation in asthmatic and control subjects","volume":"159","author":"Chanez","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1046\/j.1365-2222.2000.00804.x","article-title":"Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis","volume":"30","author":"Gaga","year":"2000","journal-title":"Clin. Exp. Allergy"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.1365-2222.2003.01652.x","article-title":"Mucosal and systemic inflammatory changes in allergic rhinitis and asthma: A comparison between upper and lower airways","volume":"33","author":"Braunstahl","year":"2003","journal-title":"Clin. Exp. Allergy"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1164\/ajrccm.161.6.9906121","article-title":"Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients","volume":"161","author":"Braunstahl","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1398-9995.2005.00725.x","article-title":"Nasal polyposis and its impact on quality of life: Comparison between the effects of medical and surgical treatments","volume":"60","author":"Alobid","year":"2005","journal-title":"Allergy"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/0003-4819-154-5-201103010-00003","article-title":"Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: A randomized trial","volume":"154","author":"Vaidyanathan","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/alr.22431","article-title":"Predictors of efficacy for combination oral and topical corticosteroids to treat patients with chronic rhinosinusitis with nasal polyps","volume":"9","author":"Epperson","year":"2019","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/all.70237","article-title":"Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications-An EAACI Task Force Report","volume":"81","author":"Reitsma","year":"2026","journal-title":"Allergy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/all.70131","article-title":"Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments","volume":"81","author":"Bousquet","year":"2026","journal-title":"Allergy"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Alexandru, V., Manole, A., Groza, L.S., and Manole, F. (2026). United Airway Disease: An Evolving Concept? A Scoping Review of the Modern Literature on Integrated Treatment Approaches. Life, 16.","DOI":"10.3390\/life16020220"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/all.15679","article-title":"Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis","volume":"78","author":"Bousquet","year":"2023","journal-title":"Allergy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1111\/all.14314","article-title":"A novel whole blood gene expression signature for asthma, dermatitis, and rhinitis multimorbidity in children and adolescents","volume":"75","author":"Lemonnier","year":"2020","journal-title":"Allergy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/ACI.0000000000000124","article-title":"Discovering susceptibility genes for allergic rhinitis and allergy using a genome-wide association study strategy","volume":"15","author":"Li","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bunyavanich, S., Melen, E., Wilk, J.B., Granada, M., Soto-Quiros, M.E., Avila, L., Lasky-Su, J., Hunninghake, G.M., Wickman, M., and Pershagen, G. (2011). Thymic stromal lymphopoietin (TSLP) is associated with allergic rhinitis in children with asthma. Clin. Mol. Allergy, 9.","DOI":"10.1186\/1476-7961-9-1"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Choi, B.Y., Han, M., Kwak, J.W., and Kim, T.H. (2021). Genetics and Epigenetics in Allergic Rhinitis. Genes, 12.","DOI":"10.3390\/genes12122004"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S2213-2600(18)30052-3","article-title":"DNA methylation in childhood asthma: An epigenome-wide meta-analysis","volume":"6","author":"Xu","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jaci.2019.12.911","article-title":"Nasal DNA methylation profiling of asthma and rhinitis","volume":"145","author":"Qi","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2020.11.044","article-title":"Shared DNA methylation signatures in childhood allergy: The MeDALL study","volume":"147","author":"Xu","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Luo, W., Hu, J., Xu, W., and Dong, J. (2022). Distinct spatial and temporal roles for Th1, Th2, and Th17 cells in asthma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.974066"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kokubo, K., Onodera, A., Kiuchi, M., Tsuji, K., Hirahara, K., and Nakayama, T. (2022). Conventional and pathogenic Th2 cells in inflammation, tissue repair, and fibrosis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.945063"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.mayocp.2021.04.025","article-title":"Eosinophils in Health and Disease: A State-of-the-Art Review","volume":"96","author":"Wechsler","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1111\/all.15751","article-title":"Eosinophils from A to Z","volume":"78","author":"Gigon","year":"2023","journal-title":"Allergy"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jaci.2016.09.011","article-title":"Innate lymphoid cells in allergic and nonallergic inflammation","volume":"138","author":"Morita","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"011","DOI":"10.24966\/ADT-749X\/100014","article-title":"Bronchial hyperreactivity (BHR): An old but gold hallmark of asthma","volume":"6","author":"Boccabella","year":"2023","journal-title":"Allergy Disord. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pcrj.2006.05.004","article-title":"In vitro diagnosis of allergy: How to interpret IgE antibody results in clinical practice","volume":"15","author":"Ahlstedt","year":"2006","journal-title":"Prim. Care Respir. J."},{"key":"ref_70","unstructured":"(2026, June 01). GINA Strategy Report\u2014Global Initiative for Asthma\u2014GINA. Available online: https:\/\/ginasthma.org\/2026-gina-strategy-report."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2009.06.014","article-title":"\u201cReal-life\u201d effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study","volume":"103","author":"Brusselle","year":"2009","journal-title":"Respir. Med."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Maniscalco, M., Fuschillo, S., Mormile, I., Detoraki, A., Sarnelli, G., de Paulis, A., Spadaro, G., and Cantone, E. (2023). Exhaled Nitric Oxide as Biomarker of Type 2 Diseases. Cells, 12.","DOI":"10.3390\/cells12212518"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/thorax-2022-219268","article-title":"Effect of obesity on airway and systemic inflammation in adults with asthma: A systematic review and meta-analysis","volume":"78","author":"Scott","year":"2023","journal-title":"Thorax"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"(2005). ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am. J. Respir. Crit. Care Med., 171, 912\u2013930.","DOI":"10.1164\/rccm.200406-710ST"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"(2025). BTS\/NICE\/SIGN joint guideline on asthma: Diagnosis, monitoring and chronic asthma management (November 2024)\u2014Summary of recommendations. Thorax, 80, 416\u2013424.","DOI":"10.1136\/thorax-2024-222910"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S2213-2600(25)00037-2","article-title":"Inflammatory and clinical risk factors for asthma attacks (ORACLE2): A patient-level meta-analysis of control groups of 22 randomised trials","volume":"13","author":"Meulmeester","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaci.2023.06.005","article-title":"Eosinophils and tissue remodeling: Relevance to airway disease","volume":"152","author":"Siddiqui","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1365-2222.2009.03439.x","article-title":"Nasal eosinophilia: An indicator of eosinophilic inflammation in asthma","volume":"40","author":"Amorim","year":"2010","journal-title":"Clin. Exp. Allergy"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/19458924231173205","article-title":"The Role of Fractional Exhaled Nitric Oxide in Diagnosing Asthmatic Type 2 Chronic Rhinosinusitis with Nasal Polyps","volume":"37","author":"Park","year":"2023","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/JAA.S351720","article-title":"Role of Thymus and Activation-Regulated Chemokine in Allergic Asthma","volume":"15","author":"Quoc","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/all.13496","article-title":"Precision medicine in united airways disease: A \u201ctreatable traits\u201d approach","volume":"73","author":"Yii","year":"2018","journal-title":"Allergy"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/19458924231190568","article-title":"Systematic Review of Protein Biomarkers in Adult Patients with Chronic Rhinosinusitis","volume":"37","author":"Gokani","year":"2023","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/S0140-6736(25)01625-3","article-title":"Anti-cytokine biologics for asthma in adults","volume":"406","author":"Israel","year":"2025","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.jaip.2025.04.043","article-title":"Reappraisal of Biologic Efficacy from Phase 3 Trials in Refractory Chronic Rhinosinusitis and Nasal Polyps","volume":"13","author":"Lipworth","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_86","first-page":"1","article-title":"Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: A change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology","volume":"42","author":"Bellocchi","year":"2022","journal-title":"ACTA Otorhinolaryngol. Ital."},{"key":"ref_87","unstructured":"(2026, June 29). GINA 2026 Severe Asthma Guide\u2014Now Available!\u2014Global Initiative for Asthma\u2014GINA. Available online: https:\/\/ginasthma.org\/gina-2026-severe-asthma-guide-now-available\/."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaci.2014.08.025","article-title":"The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy","volume":"135","author":"Namazy","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Matz","year":"2001","journal-title":"Eur. Respir. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"240088","DOI":"10.1183\/16000617.0088-2024","article-title":"Biologics in severe asthma: A state-of-the-art review","volume":"34","author":"Gyawali","year":"2025","journal-title":"Eur. Respir. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): A randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for Inadequately Controlled Asthma with Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 Study of Reslizumab in Patients with Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1111\/bcp.16087","article-title":"Pharmacokinetics\/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial","volume":"90","author":"Emson","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy\/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients with Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"ref_115","first-page":"301","article-title":"Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP","volume":"59","author":"Desrosiers","year":"2021","journal-title":"Rhinol. J."},{"key":"ref_116","unstructured":"Fda, C. (2026, June 29). Highlights of Prescribing Information, Available online: www.fda.gov\/medwatch."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in Adults with Uncontrolled Asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): A randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Lipworth, B.J., Allahyar, A., Cardner, M., Sutton, D., Cartwright, J., Lehmann, M., De Baets, G., Muthas, D., Platt, A., and Li, T. (2025). Tezepelumab reduces inflammatory biomarkers in adults with severe chronic rhinosinusitis with nasal polyps with and without comorbid asthma: Results from the phase 3 WAYPOINT study. Eur. Respir. J., 66.","DOI":"10.1183\/13993003.congress-2025.OA2336"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): Phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Heffler, E.M., Jacques, L., Zhu, C.Q., Vichiendilokkul, A., Howarth, P., and Pavord, I.D. (2025). Twice-yearly depemokimab demonstrates efficacy in patients with asthma and comorbid chronic rhinosinusitis with nasal polyps (CRSwNP): Phase III SWIFT-1\/2 studies. Eur. Resp. J., 66.","DOI":"10.1183\/13993003.congress-2025.OA2334"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Menzies-Gow, A., Colice, G., Griffiths, J.M., Almqvist, G., Ponnarambil, S., Kaur, P., Ruberto, G., Bowen, K., Hellqvist, \u00c5., and Mo, M. (2020). NAVIGATOR: A phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir. Res., 21.","DOI":"10.1186\/s12931-020-01526-6"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S2213-2600(25)00287-5","article-title":"Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): A multicentre, randomised, double-blind, head-to-head phase 4 trial","volume":"13","author":"Canonica","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Tsukada, A., Tsurumaki, N., Terada-Hirashima, J., Takasaki, J., Nishimura, N., Nokihara, H., Izumi, S., and Hojo, M. (2025). Comparative efficacy of biologics for uncontrolled asthma patients with chronic rhinosinusitis or nasal polyps: A systematic review and network meta-analysis. BMC Pulm. Med., 25.","DOI":"10.1186\/s12890-025-03911-7"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3897\/pharmacia.73.e188786","article-title":"Clinical outcomes in severe asthma patients switching biologic therapies: A real-world cohort analysis","volume":"73","author":"Krusheva","year":"2026","journal-title":"Pharmacia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/JAA.S507008","article-title":"Combining Dual Biologics Therapy for Severe Asthma: A Series of Ten Cases","volume":"18","author":"Chen","year":"2025","journal-title":"J. Asthma Allergy"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Seccia, V., D\u2019amato, M., Scioscia, G., Bagnasco, D., Di Marco, F., Fadda, G., Menzella, F., Pasquini, E., Pelaia, G., and Tremante, E. (2023). Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach. J. Pers. Med., 12.","DOI":"10.3390\/jpm12071096"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/ajrccm\/aamaf135","article-title":"Fractional exhaled nitric oxide as a novel biomarker of relapse in eosinophilic granulomatosis with polyangiitis","volume":"2026","author":"Cefaloni","year":"2026","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"100592","DOI":"10.1016\/j.waojou.2021.100592","article-title":"ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments","volume":"14","author":"Lombardi","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Tomasello, A., Benfante, A., Principe, S., and Scichilone, N. (2025). Early Initiation of Biologic Therapies to Prevent Severe Asthma Progression. Medicina, 61.","DOI":"10.3390\/medicina61101797"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S2213-2600(25)00299-1","article-title":"Reframing remission in severe asthma: A conceptual framework for distinguishing disease activity versus damage","volume":"13","author":"Porsbjerg","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): A randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2400404","DOI":"10.1183\/13993003.00404-2024","article-title":"Titration of anti-IL-5 biologics in severe asthma: An open-label randomised controlled trial (the OPTIMAL study)","volume":"64","author":"Soendergaard","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"100502","DOI":"10.1016\/j.waojou.2020.100502","article-title":"Biologics and global burden of asthma: A worldwide portrait and a call for action","volume":"14","author":"Caminati","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaci.2026.02.041","article-title":"Food and Drug Administration regulation of biosimilar products: Improving affordability of biologics for patients with asthma and allergic diseases","volume":"157","author":"Khan","year":"2026","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/5\/568\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:48:58Z","timestamp":1789382938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/5\/568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":137,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medsci14050568"],"URL":"https:\/\/doi.org\/10.3390\/medsci14050568","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}